EUVIMEDEUVIMED entdecken
Crossref

Neurologic Symptoms After 177 Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience

Gokce Belge Bilgin, Brian J Burkett, Cem Bilgin, Jacob J Orme, Daniel S Childs, Miguel Muniz Rincon, Ahmad S Abdelrazek, Derek R Johnson, Geoffrey B Johnson, Eugene D Kwon, Oliver Sartor, Ayse Tuba Kendi

Journal of Nuclear Medicine · 2024-09 · 65 (9) · 1402-1408

DOI: 10.2967/jnumed.124.267643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 01.08.2024. Verfasst von Gokce Belge Bilgin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, Minnesota; belgebilgin.gokce@mayo.edu. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 1-Ring, Dipeptides, Lutetium. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 1-RingDipeptidesLutetiumHumansMaleAgedMiddle AgedAged, 80 and overRetrospective StudiesProstatic Neoplasms, Castration-ResistantNervous System DiseasesProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMA-617neurologic findingsprostate cancerradionuclide therapytheranostics

Substanzen

Heterocyclic Compounds, 1-RingDipeptidesLutetiumPluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, Mayo Clinic, Rochester, Minnesota; belgebilgin.gokce@mayo.edu.
  • Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Department of Oncology, Mayo Clinic, Rochester, Minnesota.
  • Department of Immunology, Mayo Clinic, Rochester, Minnesota; and.
  • Department of Urology, Mayo Clinic, Rochester, Minnesota.

Zitieren

APA

Belge Bilgin, G., Burkett, B. J., Bilgin, C., Orme, J. J., Childs, D. S., Rincon, M. M., Abdelrazek, A. S., Johnson, D. R., Johnson, G. B., Kwon, E. D., Sartor, O., & Kendi, A. T. (2024). Neurologic Symptoms After 177 Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. Journal of Nuclear Medicine, 65(9), 1402-1408. https://doi.org/10.2967/jnumed.124.267643

Vancouver

Belge Bilgin G, Burkett BJ, Bilgin C, Orme JJ, Childs DS, Rincon MM, et al. Neurologic Symptoms After 177 Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. Journal of Nuclear Medicine. 2024;65(9):1402-1408. doi:10.2967/jnumed.124.267643

BibTeX
@article{BelgeBilgin2024,
  author = {Belge Bilgin, Gokce and Burkett, Brian J and Bilgin, Cem and Orme, Jacob J and Childs, Daniel S and Rincon, Miguel Muniz and Abdelrazek, Ahmad S and Johnson, Derek R and Johnson, Geoffrey B and Kwon, Eugene D and Sartor, Oliver and Kendi, Ayse Tuba},
  title = {Neurologic Symptoms After 177 Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {9},
  pages = {1402--1408},
  doi = {10.2967/jnumed.124.267643}
}
Kostenlos starten →